Merck & Co. has entered into an agreement with Quotient Therapeutics to utilize the biotech’s somatic genomics platform in the search for new drug targets for inflammatory bowel disease (IBD). The deal includes an upfront payment of $20 million from Merck, with the potential for additional development, regulatory, and commercial milestone payments that could bring the total value of the agreement to $2.2 billion.
Quotient Therapeutics, founded by Flagship Pioneering, has developed a platform designed to analyze patient tissue for somatic genetic mutations within the context of disease. The company states that its approach aims to identify mutations that either contribute to or protect against specific conditions. According to Quotient, the somatic genome consists of trillions of distinct genomes that arise from mutations occurring in cells. These mutations begin before birth and continue throughout life due to both internal biological processes and external influences.
The collaboration reflects Merck’s ongoing focus on immunology, particularly in the IBD space. The company has previously made a significant investment in this area through its acquisition of Prometheus Biosciences in 2023 for nearly $11 billion. That acquisition included tulisokibart, an anti-TL1A monoclonal antibody candidate currently being evaluated in late-stage clinical trials.
Tulisokibart is undergoing phase 3 studies in ulcerative colitis and Crohn’s disease under the trial names Atlas-UC and Ares-CD. In addition, Merck initiated phase 2b trials in October to investigate the therapy’s potential in other conditions, including moderate to severe hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis.
Commenting on the new partnership, Marc Levesque, M.D., Ph.D., vice president of discovery at Merck Research Laboratories, said, “Quotient’s platform has the potential to provide us with unique biological insights into genomic changes that are naturally occurring within patients with IBD.” He added that millions of individuals worldwide are affected by the disease and noted the absence of treatments that modify its progression.
Quotient’s technology has attracted attention from multiple large pharmaceutical companies in recent years. In a separate agreement announced last fall, GSK partnered with Flagship Pioneering in a deal valued at up to $7 billion in potential payments. This collaboration included work with Quotient and another Flagship-founded company, Profound Therapeutics, to identify drug targets for liver diseases. Under that arrangement, each selected program could yield up to $720 million in payments to Flagship and its associated companies.
As part of its work with GSK, Quotient is currently engaged in three distinct research programs focused on chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and metabolic dysfunction-associated steatohepatitis.
The company is also collaborating with Pfizer through a broader partnership with Flagship Pioneering. In August 2024, Pfizer expanded its agreement to include Quotient in a 10-program initiative aimed at discovering new therapeutic targets, including those related to cardiovascular and renal diseases.
Quotient Therapeutics was established by Flagship Pioneering in 2022 and formally introduced to the public the following year. Since then, its somatic genomics platform has been incorporated into multiple collaborations aimed at advancing drug discovery across a range of disease areas.
Merck Expands IBD Research with Strategic Investment
Merck has taken a significant step in advancing inflammatory bowel disease research as Merck commits $20 million upfront to partner with Quotient Therapeutics. This collaboration gives Merck access to Quotient’s cutting-edge somatic genomics platform, which is designed to uncover novel disease mechanisms and therapeutic targets.
Why Merck Is Investing in Somatic Genomics
Merck is focusing on somatic genomics to better understand the genetic mutations that drive complex diseases like IBD. By leveraging this platform, Merck aims to identify new pathways that traditional genomic approaches may miss. This move highlights Merck’s commitment to innovation and precision medicine.
Potential Impact on IBD Treatment Development
Merck expects that this partnership will accelerate the development of targeted therapies for inflammatory bowel disease. With access to Quotient’s advanced technology, Merck can improve drug discovery efficiency and potentially bring more effective treatments to patients suffering from chronic gastrointestinal conditions.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
